TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that its wholly-owned subsidiary, PharmAla Biotech Australia, has contracted with a UK-based CDMO to execute manufacture of its ALA-002 drug substance. “PharmAla Australia worked diligently, executing a global RFP search ...

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $150 million, b ...

文章核心观点 - Dyadic Applied BioSolutions 与 Opes Diagnostics Limited 达成商业协议 旨在利用Opes在欧洲、以色列和亚洲的现有商业关系与市场经验 加速其重组蛋白产品组合在无血清细胞培养基应用领域的市场渗透和商业化进程 [1][2][3] 合作协议内容 - 协议涉及产品包括Dyadic的重组人转铁蛋白、牛转铁蛋白、人成纤维细胞生长因子和牛成纤维细胞生长因子产品 用于生命科学、食品和营养市场的无血清细胞培养基应用 [1] - 根据协议 Opes将主要负责在欧洲、以色列和亚洲市场识别并接触潜在客户 以加速Dyadic重组蛋白产品组合在细胞培养基及相关应用领域的市场进入 [2] - Dyadic保留了直接销售以及与全球其他合作伙伴合作的权利 [2] 合作目标与预期影响 - 合作旨在加速Dyadic利用其微生物表达平台生产的重组蛋白产品在多个行业的渗透 包括研究、诊断、培养肉和生命科学生物制造领域 这些行业需要可靠、可扩展且具成本效益的生长因子和功能蛋白来源 [3] - Opes已向生命科学、食品和营养领域使用无血清细胞培养基的多个客户提供了产品样品 [3] - Dyadic管理层表示 此次合作通过与其服务领域内拥有强大现有行业关系的伙伴合作 扩展了公司在目标市场的重组蛋白产品组合 支持其商业目标 [4] - Opes的市场影响力和客户网络有望帮助推动Dyadic的细胞培养基产品在扩张的市场中被采用 并进一步推动公司从以开发活动为主向更广泛的商业参与转变 [4] 公司业务背景 - Dyadic Applied BioSolutions 是一家全球生物技术公司 利用其专有的微生物平台生产重组蛋白 销售或授权给生命科学、食品和营养以及生物工业市场的合作伙伴 [5] - 其C1和Dapibus™表达系统支持灵活、具成本效益的制造 是不断增长的商业和合作项目组合的基础 [5] - Opes Diagnostics Limited 是一家总部位于英国的诊断工具、实验室耗材和生物试剂供应商 在欧洲和其他国际市场拥有成熟的客户关系 为生物技术、诊断及相关领域的一系列产品提供商业化支持 [6]

SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses. Pursuant to the ...

公司股价表现 - Zenas BioPharma (ZBIO) 股票在过去一年中展现出强劲的积极势头 [1] - 年初至今，该公司股价上涨了395%，表现大幅超越标普500指数 [1] 公司研发管线 - 公司拥有两款处于研发后期的资产，即obexelimab [1] 分析师背景 - 分析师拥有细胞生物学硕士学位，并曾作为实验室技术员在药物发现诊所工作多年，在细胞培养、检测方法开发和治疗研究方面拥有丰富的实践经验 [1] - 该科学背景使其深刻理解药物开发背后的严谨性和挑战性 [1] - 过去五年活跃于投资领域，其中最近四年在从事实验室工作的同时，兼任生物技术股票分析师 [1] - 分析重点在于识别以独特和差异化方式进行创新的生物技术公司，无论是通过新颖的作用机制、同类首创疗法，还是具有潜力改变治疗模式的平台技术 [1] - 分析方法强调结合实验室科学专业知识与金融和市场分析，旨在提供技术可靠且以投资为导向的研究 [1] - 在Seeking Alpha上，计划主要撰写生物技术领域的文章，覆盖从早期临床管线到商业阶段生物技术公司等不同发展阶段的公司 [1] - 分析方法侧重于评估候选药物背后的科学原理、竞争格局、临床试验设计和潜在市场机会，同时平衡财务基本面和估值 [1] - 分析师认为，生物技术领域是突破性科学可以转化为超额回报的行业，但也需要仔细审视 [1]

核心观点 - Ascendis Pharma (ASND) 因可能在近期被收购的消息而引发市场讨论 [1] - 该公司在2024年11月公布的2025财年第三季度业绩表现强劲 [1] 公司财务状况与事件 - 2025财年第三季度业绩表现强劲 [1] 行业与分析师背景 - 分析师的背景结合了细胞生物学硕士学位、药物发现实验室技术员的实践经验以及五年的投资领域经验 [1] - 过去四年，分析师在从事实验室工作的同时，兼任生物技术股票分析师 [1] - 分析师专注于识别通过新颖作用机制、同类首创疗法或具有重塑治疗范式潜力的平台技术进行独特创新的有前景的生物技术公司 [1] - 分析方法强调评估候选药物背后的科学原理、竞争格局、临床试验设计和潜在市场机会，同时平衡财务基本面和估值 [1] - 生物技术领域突破性科学可以转化为超额回报，但也需要仔细审查 [1]

PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become e ...

PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become ...

STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is exp ...

Much like pharmaceutical packaging, the most important part of this story is in the fine print. Last week, the US House overwhelmingly voted in favor of Congress’s mammoth annual defense policy bill, which would authorize $900 billion in military funding. Inside the omnibus package was the Biosecure Act, a piece of legislation targeting Chinese biotechs that could have unintended consequences. SUBSCRIBE:  Receive more of our free The Daily Upside newsletter. READ ALSO: Bigger Social Security Checks Top 2 ...